A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults with Relapsed or Refractory Disease

We are doing this study because we want to find out if this approach is better or worse than the usual approach for acute lymphoblastic leukemia. The usual approach is defined as: care most people get for acute lymphoblastic leukemia.